Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant sars-cov-2 vaccine (chimpanzee adenoviral vector)
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant SARS-CoV-2 vaccine (chimpanzee adenoviral vector), identified by the code name Y2020, is a viral vector vaccine developed by Walvax Biotechnology in collaboration with Tsinghua University and Tianjin Medical University. It utilizes a replication-deficient chimpanzee adenovirus platform to deliver the genetic sequence encoding the spike (S) protein of the SARS-CoV-2 virus. Upon intramuscular injection, the viral vector enters host cells and facilitates the expression of the spike protein, which acts as an antigen to trigger both humoral and cellular immune responses. This vaccine candidate was designed to provide protection against COVID-19 and has progressed through Phase 1 and Phase 2 clinical trials to evaluate its safety, tolerability, and immunogenicity. While Walvax has also pursued mRNA-based vaccine candidates, the chimpanzee adenoviral vector platform remains a significant part of its infectious disease portfolio.
- Other names
- Walvax chimpanzee adenovirus vector COVID-19 vaccineRecombinant Novel Coronavirus Vaccine (Chimpanzee Adenovirus Vector)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on recombinant sars-cov-2 vaccine (chimpanzee adenoviral vector).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant sars-cov-2 vaccine (chimpanzee adenoviral vector).